

Drug Discovery Symposium

**Bloomberg Lecture Hall
Institute for Advanced Study, Princeton, NJ**

Hosted by:

**THE SIMONS CENTER FOR SYSTEMS BIOLOGY
Arnold J. Levine, Professor**

**With Generous Support from
Devon Park Bioventures
Venrock**

SYMPOSIUM SCHEDULE

Wednesday, September 17, 2008

- 8:15 a.m. - 8:55 a.m.** **COFFEE AVAILABLE** - Bloomberg Hall Biology Atrium
- 8:55 a.m. - 9:00 a.m.** **Welcoming Remarks**
Arnold J. Levine, Institute for Advanced Study
- 9:00 a.m. - 9:40 a.m.** **Michael C. Venuti, BioSeek, Inc.**
Picking Winners at the Discovery Stage of Drug Development
- 9:40 a.m. - 10:20 a.m.** **Julian Adams, Infinity Pharmaceuticals, Inc.**
*Development of the Novel Hsp90 Inhibitor IPI-504 and
Insights into the Tumor Cell Selectivity of Hsp90 Inhibitors*
- 10:20 a.m. - 10:40 a.m.** **COFFEE BREAK** - Bloomberg Hall Biology Atrium
- 10:40 a.m. - 11:20 a.m.** **Neal Rosen, Memorial Sloan-Kettering Cancer Center**
Mechanism-Based Combination Therapy
- 11:20 a.m. - 12:00 p.m.** **George D. Demetri, Dana-Farber Cancer Institute,
Harvard Medical School and Ludwig Institute for Cancer
Research**
*Targeting Validated Oncogenic Mechanisms to Improve
Anticancer Drug Discovery and Development*
- 12:00 p.m. - 12:40 p.m.** **Matthew L. Meyerson, Dana-Farber Cancer Institute,
Harvard Medical School & Broad Institute of Harvard and
MIT**
Genomic Alterations in Human Cancer
- 12:40 p.m. - 2:00 p.m.** **LUNCH** – Available in Institute Dining Hall

Drug Discovery Symposium

Wednesday, September 17, 2008 (continued)

- 2:00 p.m. - 2:40 p.m.** **Todd Golub, Broad Institute, Dana-Farber Cancer Institute, Harvard Medical School and HHMI**
Signatures for Small Molecule Discovery
- 2:40 p.m. - 3:20 p.m.** **Alexei Vazquez, Institute for Advanced Study**
Identifying Single Nucleotide Polymorphisms that Affect Human Cancer Using the NCI60 Human Tumor Cell Line Anticancer Drug Screen
- 3:20 p.m. - 3:40 p.m.** **AFTERNOON TEA BREAK - Fuld Hall Common Room**
- 3:40 p.m. - 4:20 p.m.** **Charles L. Sawyers, Memorial Sloan-Kettering Cancer Center and HHMI**
Overcoming Resistance to Molecularly Targeted Therapy
- 4:20 p.m. - 5:00 p.m.** **Daniel A. Haber, Massachusetts General Hospital Cancer Center**
*Molecular Analysis of Circulating Tumor Cells:
A Guide for Genotype-Directed Cancer Therapies*
- 5:00 p.m. - 6:00 p.m.** **PANEL DISCUSSION**
Arnold J. Levine - Moderator
Stephen Friend, Merck & Co., Inc.
William N. Hait, Johnson & Johnson
Robert Kramer, Bristol-Myers Squibb
Allen I. Oliff, GlaxoSmithKline